Physician profile
Mark A Lapp
NPI 1881664977
$18,144.70
in general payments reported to CMS, 2019-2025
8 companies · $4,336 in 2025
The $4,336 reported for 2025 was more than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2021: $159 · 2022: $4,424 · 2023: $331 · 2024: $8,535 · 2025: $4,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,450 · Travel and Lodging: $4,088 · Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,450.00 |
| Travel and Lodging | $4,087.94 |
| Food and Beverage | $663.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carlsmed, INC. | $12,707.97 | 2022-2025 | Aprevo |
| Cerapedics INC. | $3,374.44 | 2022 | |
| Depuy Synthes Products, INC. | $900.00 | 2022 | |
| Medical Device Business Services, INC. | $500.54 | 2021-2025 | Velys |
| Abyrx, INC | $253.86 | 2019 | |
| Depuy Synthes Sales INC. | $244.49 | 2019-2021 | |
| Bioventus LLC | $147.69 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $15.71 | 2023 | Exparel, Zilretta, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.